Berlin Heals funding has surpassed $10 million following a newly completed financing round aimed at expanding access to its less invasive heart failure treatment. The MedTech company secured investments from both existing shareholders and new investors to advance its cardiac microcurrent technology and support clinical research.
The funding marks a significant step toward improving treatment options for heart failure patients while accelerating the company’s regulatory and commercialization strategy.
Expanding Innovation in Heart Failure Treatment
Berlin Heals has developed C-MIC (Cardiac Microcurrent), a proprietary implantable device designed to improve cardiac function by delivering a constant electrical microcurrent to the heart. Clinical studies have already shown promising functional and quality-of-life improvements in patients with dilated cardiomyopathy.
Now, the company plans to refine device designs and focus on less invasive implantation techniques. These improvements aim to broaden patient eligibility and simplify adoption for healthcare providers.
Berlin Heals Funding Supports Clinical Trials
The newly secured Berlin Heals funding will help expand indications into wider patient populations. Additionally, the company intends to launch larger double-blinded trials to prepare for an FDA Investigational Device Exemption (IDE) submission.
Berlin Heals also expects to present updated clinical data at major cardiology conferences and publish new research findings throughout the year. Long-term follow-up data continues to reinforce confidence in the therapy’s durability and clinical value.
Leadership Highlights Strategic Milestone
John Brumfield, Chief Executive Officer of Berlin Heals Holding AG, described the financing round as an important milestone. He emphasized that strong investor backing and positive clinical data position the company to move decisively toward less invasive solutions and global commercialization.
Board Chairman Rob ten Hoedt added that heart failure remains a major unmet medical need worldwide. He noted that the technology has the potential to reshape treatment approaches and improve patient quality of life on a global scale.
Building Momentum for Global Impact
Founded in 2014, Berlin Heals is a Swiss joint-stock company dedicated to transforming heart failure care. Its C-MIC technology generates a localized electrical field that supports improved heart performance.
With fresh capital and expanding clinical evidence, Berlin Heals is strengthening its role in next-generation cardiac therapy while working to bring effective treatment to more patients worldwide.
Read Also: Sandy Voss Appointment: Joins Life Science Connect as SVP
